Welcome to BioRN Biotech Cluster Rhine-Neckar Delegation of the … Heidelberg/2015-06-10...

Preview:

Citation preview

Welcome to BioRN Biotech Cluster Rhine-Neckar

Delegation of the Limburgse Werkgevers Vereniging

Christian Tidona Heidelberg, June 10, 2015

My Entrepreneurial Journey

1999: PhD Molecular Virology

2000: Multimetrix (Diagnostics)

2002: Cytonet (Cell Therapy)

2008: HI-STEM (Cancer Research)

2009: BioRN (Regional Development)

2013: BioMed X (Innovation Center)

2 www.bio.mx BioMed X Innovation Center

History of the BioRN Cluster

1984: Foundation of Heidelberg Technology Park

1996: Winner of BioRegio Competition 1997-2001: 35 Projects / €26.1m grant + 31,3m industry contribution Focus: Generation of startups

2008: Winner of Leading-Edge Cluster Competition 2009-2013: 44 Projects / €40m grant + €40m industry contribution Focus: Economic value creation

2015: Winner of Cluster Internalization Grant 2016-2019: €4m grant + €4m industry contribution Focus: Extension of Health Axis Europe, SME Launchpad

3

Cell-Based and Molecular Medicine 95 Biotech companies with R&D

3,800 Jobs

3 Global Players 16,000 Jobs

6 Universities and Research Institutions 15,000 Jobs

BioRN Cluster

Partners

4

Large Biotech and Pharma Companies

Biotech SMEs

Academic Education and Research

BioRN Cluster

Scientific Excellence

5

University of Heidelberg

Highest ranked German university (#29) in the top 100 of the QS World University Rankings 2013 in life sciences

Heidelberg University Hospital

Highest ranked university clinic in the German CHE Research Ranking 2009 (11,700 employees, 1,900 beds, annual budget: 1.1 billion €)

German Cancer Research Center (DKFZ)

Largest biomedical research center in Germany, international leader in cancer research (3,000 employees)

European Molecular Biology Laboratory (EMBL)

One of the world's top research institutions for molecular biology and bioinformatics (1,400 employees)

BioRN Cluster

Campus Infrastructure

6

Heidelberg Life Science Campus Neuenheimer Feld • 140 hectares • Technology Park: 50,000 sqm lab

and office space for companies

New Life Science Campus Bahnstadt •20 hectares •Sky Labs: 20,000 sqm lab and office space

7

44 Projects, 43 Partners (32 Private, 11 Public) €40M Grant (+ €40M Industry Funding) 38 Patent Applications 34 Journal Publications 13 SME Financing Rounds (€118M) 4 Licensing Deals (Upfront >€60M, MS >€500M) 2 M&A Deals (€266M)

BioRN Leading-Edge Cluster Funding Summary of Results (2009-2013)

Vorführender
Präsentationsnotizen
Partner: 27 Zuwendungsempfänger (Unternehmen), Unterauftragnehmer: 11 Akademia / 5 Unternehmen Primäreffekt: >5,6x BMBF-Mittel (€32M Zuschuss vs. >€178M Finanzierungsrunden und Upfront) 48,6x Landes-Mittel (€3,7M Zuschuss vs. >€178M Finanzierungsrunden und Upfront) KMU Finanzierungsrunden: HI-STEM (€15M, 2008, Hopp Foundation/DKFZ) mtm laboratories (€7M, September 2009) Sygnis (€10M, October 2009) Affimed (€20M, April 2010 + €15M, 2012) Cytonet (€11.9M, December 2009 and August 2010, + €12M, 2011 und €10.5M, 2012) Elara (€2.6M, September 2009) Heidelberg Pharma (€1M, May 2010) Apogenix (€7.5M, January 2012) Phenex (€5M 2012) Lizenzverträge (Upfront / Milestone Payment) Cellzome GSK (€33M/€475M) Cellzome Neusentis Ascendis Sanofir Aventis Phenex Janssen (US$135M = €103.5M) (eigene Angabe Phenex: €105M in 2012) M&A Verträge (Upfront / Milestone Payment) mtm (€130M/€60M Übernahme durch Roche) Cellzome (€76M Übernahme durch GSK) März 2010| Cellzome (Teilprojekt INE-01) Kooperations-/Lizenzvertrag mit GlaxoSmithKline Sofortzahlung von 33 Mio. € / erfolgsabhängige Meilensteinzahlungen bis zu 475 Mio. € Dezember 2010| Ascendis Pharma (Teilprojekt INC-02) Lizenzvertrag mit Sanofi Aventis Mai 2011| Cellzome (Teilprojekt INE-01) Kooperations-/Lizenzvertrag mit Neusentis (Pfizer) Juli 2011| MTM Laboratories (Teilprojekt BMC-07) Übernahme durch Roche Sofortzahlung von 130 Mio. € / erfolgsabhängige Meilensteinzahlungen bis zu 60 Mio. € Mai 2012| Cellzome (Teilprojekt INE-01) Übernahme durch GlaxoSmithKline Sofortzahlung von 76 Mio. € für restliche 80% Anteile Dezember 2012| Phenex Pharmaceuticals (Teilprojekt INB-10) Lizenzvertrag mit Janssen Biotech Upfront-Zahlung und Meilenstein-Zahlungen bis zu 135 Millionen US$

BioRN Cluster Management

EU Gold Label

8

Source: http://whatmatters.mckinseydigital.com/flash/innovation_clusters/

Silicon Valley

Innovation Clusters with Critical Mass

USA

EU Innovation Clusters with Critical Mass

Source: http://whatmatters.mckinseydigital.com/flash/innovation_clusters/

Ci3 – Cluster for Individualized Immune Intervention

BioRN – Cluster for Cell-Based and Molecular Medicine

Rhine-Main-Neckar Supercluster

+ about 150 SMEs with R&D

Mainz

Heidelberg

Fostering Health Innovation Across Europe

Health Axis Europe

12

Vorführender
Präsentationsnotizen
Constitution signed June 8, 2011 in Leuven

13

Strong Health Technology Clusters in Europe Matching Profiles

Cambridge Leuven Heidelberg internationally outstanding universities with

excellent health sciences and a strong tradition in top education and research

substantial health industry base driven by strong key individuals

that are personally committed to foster economic growth and entrepreneurship

special expertise in complementary health technology areas regenerative medicine and

eHealth

medical electronics and nanotechnology

personalized medicine and

cancer research

Health Axis Europe Constitution Signed

14

Leuven, June 8th, 2011 Maastricht will join June 10th, 2015

© K.U.Leuven - Rob Stevens

Vorführender
Präsentationsnotizen
From left to right: Stefan Meuer (Chairman of the Supervisory Board of BioRN Cluster Management, Director Institute of Immunology Heidelberg), Jeanette Walker (Project Director of the Cambridge Biomedical Campus), Mark Waer (Rector, K.U. Leuven), Jürgen Schwiezer (Member of the Supervisory Board of BioRN Cluster Management and former CEO Diagnostics Division & Member of the Executive Committee, F. Hoffmann-La Roche AG), Alan Barrell (Entrepreneur in Residence, University of Cambridge).

15

Health Axis Europe Objectives & Projects

Joining health innovation resources in order to increase international competitiveness HAE R&D Community: Facilitate and coordinate EU-

funded collaborative R&D projects

HAE Academy: Facilitate cross-border talent education and exchange (students, scientists, and entrepreneurs)

HAE Accelerator: Facilitate cross-border startup incubation, VC investment and syndication

http://www.health-axis.eu

16

community.health-axis.eu

17

KIC InnoLife Consortium UK CLC

Benelux CLC

French CLC

German CLC

Spanish CLC

Scandinavian CLC

Södertörn Councils

18

19

Oncology Program

Comprehensive Cancer Centers • Cancer Center Karolinska • Cambridge Cancer Centre • The Netherlands Cancer Institute

(NKI) • German Cancer Research Centre

(DKFZ) / NCT • Gustave Roussy Institute • Vall d’Hebron Institute of Oncology

accelerator.health-axis.eu

20

21

HAE Accelerator Stages & Modules

Stage 1: HAE Business Plan Competition BPC in each HAE partner region

Heidelberg Competition

Leuven Competition

Cambridge Competition

March – June 2013

Stage 2: HAE Summer Camp 4 days, Heidelberg

Training, Coaching, Mentoring

21 – 24 September 2013

top teams

25 Sept. 2013

Stage 3: HAE Expo 1 day, Heidelberg

Presentations, Awards

Ceremony, VC Partnering

HAE Accelerator Finalists

Therapeutics Diagnostics

Health IT

23

Health Axis Europe Future Perspective

HAE SME Launchpad Annual HAE Accelerator: finals rotating among

member clusters

Annual HAE Innovation Boot Camps: in each member cluster

Annual HAE Innovation Conference: rotating among member clusters

HAE SME Community: web-based platform for health SMEs across Europe

New Innovation Model: Global crowdsourcing and local incubation of the brightest ideas and talents

24 www.bio.mx BioMed X Innovation Center

New Innovation Model @ BioMed X

Global crowdsourcing: world-wide call for application Boot camp: selection of the best of

the best ideas and talents Local incubation: 2-4 year

fellowships at BioMed X Innovation Center in Heidelberg

25

Betz & Tidona (2015) Nature Biotechnology 33(1), 20-21

BioMed X

Call for Application (Example: Merck)

BioMed X 26

519 Applications from 59 countries (29x) India: 109 Male: 319 Group Leaders: 110 Germany: 100 Female: 200 Postdocs: 291 USA: 66 Postgraduates: 118 UK: 28 Spain: 28 Italy: 21 China: 19

32 Candidates selected from 10 countries (6%) Germany: 10 Male: 19 Group Leaders: 9 USA: 6 Female: 13 Postdocs: 21 UK: 4 Postgraduates: 2

Vorführender
Präsentationsnotizen
18 Open Positions: Group Leaders: 3 Postdocs: 8 Postgraduates/Technicians: 7

BioMed X 27

BioMed X Boot Camp

Vorführender
Präsentationsnotizen
Hand over of certificates to each participant

Pharma Sponsors (BioMed X Heidelberg)

BioMed X 28

Metabolism and Signaling in Cancer

Selective Kinase Inhibitors

Immunosuppressive Microenvironment of Tumors

Epigenetics and Chronic Obstructive

Pulmonary Disease

Nanomaterial-Based Biosensors for Near-Patient Testing

Tau-Mediated Neurodegeneration in Alzheimer’s Disease

“Creativity is intelligence having fun.”

Albert Einstein

BioMed X 29

Deutscher Spitzencluster 2008, unterstützt durch:

30

Recommended